Letter to Dermatology

Happle, Rudolf; Hoffmann, R.; Kokuba, Hisashi; Imafuku, Shinich; Burnett, J W; Aurelian, Laure; Örem, Asım; Çimşit, Gülseren; Değer, O.; Vanizor, Birgül; Karahan, Sevilay; Verpilleux, Marie-Pascale; Bastuji‐Garin, Sylvie; Revuz, J.; Watanabe, Mika; Matsunaga, Yuko; Katayama, Ichiro; Aubin, F.; Parriaux, N.; Robert, C.; Blanc, Dominique; Drobacheff, C.; Laurent, R.; Humbert, P; König, Anke; Lehmann, C.; Rompel, Rainer; Vocks, E.; Fluhr, Joachim W.; Barsom, O.; Gehring, W.; Gloor, M.; Grimme, H.; Petres, A.; Bergen, Elisabeth; Wiemers, S.; Schöpf, Erwin; Vanscheidt, Wolfgang; Wieme, N; Lambert, J.; Moerman, Mieke; Geerts, Marie-Louise; Temmerman, Liesbeth; Jm, Naeyaert; Yoshizawa, Yusuke; Ogasa, Shinji; Izaki, Seiichi; Kitamura, Keijiro; Kerschan, K.; Schindl, Liesbeth; Voisard, Jean-Jacques; Weill, François; Beylot‐Barry, M.; Vergier, Béatrice; Dromer, C; Beylot, C; Plötz, Sabine G.; Ring, John; Lehucher-Ceyrac, D; Salmonière, Pauline de La; Chastang, C; Morel, Patrice; Schmid, M. Hess; Dummer, Reinhard; Kempf, Werner; Hilty, N; Burg, G.; Correia, Osvaldo; Azevedo, Carolina Drumond de Barros e; Ferreira, E. Pinto; Cruz, F. Braga; Polónia, Jorge; Watanabe, Hideaki; Sueki, H.; Nakada, Tsutomu; Akiyama, Masashi; Iijima, M; Miranda‐Romero, A.; Sánchez‐Sambucety, Pedro; Gómez, J.I. Esquivias; Fernández, Matilde Martínez; Pozo, Cristina Bajo del; Fraile, Henar Aragoneses; García-Muñoz, Miguel; Viallard, Anne Marie; Lavenue, A.; Balme, B.; Pincemaille, B; Raudrant, D.; Thomas, L.; Ohnishi, Y.; Tajima, Syunji; Ishibashi, Akira; Seyama, Yousuke; Schindl, Andreas; Schindl, Martin; Pernerstorfer-Schön, Heidemarie

doi:10.1159/000018142

Cited by 8 publications

(1 citation statement)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The annual incidence of lymphomas during CsA therapy in transplant recipients varies from 1.4 to 3.6% [7, 8]and has been shown to relate more to the degree of immunosuppression than to a specific oncogenic action of the drug [9, 10]; the risk of developing a CsA-related lymphoma in these patients depends on various factors: drug dosage, duration of treatment, combination with other immunosuppressive agents and viral infections [11, 12]. …”

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous CD30+ Large T-Cell Lymphoma in a Patient with Psoriasis Treated with Cyclosporine

Corazza¹,

Zampino²,

Montanari³

et al. 2003

Dermatology

View full text Add to dashboard Cite

We report the case of a 61-year-old woman who developed an anaplastic CD30+ cutaneous T-cell lymphoma during oral cyclosporine (CsA) therapy for recalcitrant psoriasis. Two months after CsA discontinuation, clinical and histological resolution of the lymphoma was observed. However, 3 years later extracutaneous involvement of the lymphoma could be detected. The association between CsA administration and the occurrence of the lymphoma may be casual, but a relationship with immunosuppression may also be hypothesized. We have reviewed all relevant data in the literature. To our knowledge, this is the first case of primary cutaneous CD30+ anaplastic large T-cell lymphoma in a patient treated with CsA for psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous CD30+ Large T-Cell Lymphoma in a Patient with Psoriasis Treated with Cyclosporine

Corazza¹,

Zampino²,

Montanari³

et al. 2003

Dermatology

View full text Add to dashboard Cite

show abstract

The evaluation of the effectiveness and side‐effects of a 200‐mg/day constant dose of cyclosporin in chronic plaque‐type psoriasis: can a constant dose be an alternative?

Öztaş

Gürer

2003

Acad Dermatol Venereol

View full text Add to dashboard Cite

References1 Hajjeh RA, Conn LA, Stephens DS et al. Cryptococcosis in the United States: population-based multistate active surveillance and risk factors in HIV-infected persons. J Infect Dis 1999; 179 : 449 -454. 2 Gaddoni D, Resta F, Baldassari L et al. Criptococcosi cutanea in corso di AIDS. G Ital Dermatol Venereol 1993; 128 : 129 -132. 3 Vandersmissen G, Meuleman L, Tits G et al. Cutaneous cryptococcosis in corticosteroid-treated patients without AIDS. Acta Clin Belg 1996; 51 (2): 111 -117. 4 Nampoory MR, Khan ZU, Johny KV et al. Invasive fungal infections in renal transplant recipients. J Infect 1996; 33 (2): 95 -101. 5 Krcmery V Jr, Kunova A, Mardiak J. Nosocomial Cryptococcus laurentii fungemia in a bone marrow transplant patient after prophylaxis with ketoconazole successfully treated with oral fluconazole. Infection 1997; 25 (2): 130. 6 Bangert RL, Cho BR, Widders PR et al. A survey of aerobic bacteria and fungi in the feces of healthy psittacine birds. Avian Dis 1988; 32 : 46 -52. 7 Slavikova E, Vadkertiova R. Yeasts and yeast-like organisms isolated from fish-pond waters. Acta Microbiol Pol 1995; 44 (2): 181-189. 8 Bellosta M, Gaviglio MR, Mosconi M et al. Primary cutaneous cryptococcosis in an HIV-negative patient. Eur J Dermatol 1999; 9 (3): 224 -226. 9 Dimino-Emme L, Gurevitch AW. Cutaneous manifestations of disseminated cryptococcosis. J Am Acad Dermatol 1995; 32 (5, Part 2): 844 -850. 10 Kordossis T, Avlami A, Velegraki A et al. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol 1998; 36 (5): 335 -339. 11 Johnson LB, Bradley SF, Kauffman CA. Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia. References 1 Carlson JA, Murphy M. Androgen receptors and lichen sclerosus (letter). J Am Acad Dermatol 2000; 43: 559. 2 Clifton M, Smoller B. Androgen receptors and lichen sclerosus (reply). J Am Acad Dermatol 2000; 43: 559. 3 Kohlberger PD, Joura EA, Bancher D, Gitsch G, Breitenecker G, Kieback DG. Evidence of androgen receptor expression in lichen sclerosus: an immunohistochemical study. J Soc Gynecol Invest 1998; 5: 331-333. 4 Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 1999; 353: 1777-1783. 5 Carlson JA, Ambros R, Malfetano J et al. Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia. J Am Board Fam Pract 1999; 12: 473 -476. 6 Tidy JA, Soutter WP, Luesley DM, MacLean AB, Buckley CH, Ridley CM. Management of lichen sclerosus and intraepithelial neoplasia of the vulva in the UK.

show abstract

Conjunctival Squamous Cell Carcinoma following Psoriasis Treatment

et al. 2012

View full text Add to dashboard Cite

Although conjunctival SCC has been described following cyclosporine treatment for organ transplantation, this report describes a case of conjunctival SCC following lower-dose cyclosporine treatment for psoriasis in a patient who had previous psoralen plus ultraviolet A (PUVA) treatment. The conjunctival SCC should be considered in the differential diagnosis of new conjunctival lesions in such patients.

show abstract

Letter to Dermatology

Cited by 8 publications

References 2 publications

Primary Cutaneous CD30+ Large T-Cell Lymphoma in a Patient with Psoriasis Treated with Cyclosporine

Primary Cutaneous CD30+ Large T-Cell Lymphoma in a Patient with Psoriasis Treated with Cyclosporine

The evaluation of the effectiveness and side‐effects of a 200‐mg/day constant dose of cyclosporin in chronic plaque‐type psoriasis: can a constant dose be an alternative?

Conjunctival Squamous Cell Carcinoma following Psoriasis Treatment

Contact Info

Product

Resources

About